Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

W2O Reports 17th Consecutive Year of Double-Digit Revenue Growth

W2O – an innovative, analytics-driven, digital-first marketing and communications firm – reported a 23 percent increase in revenue to $177 million in 2018 from $144 million in 2017.

Read More »

Biogen to buy Nightstar Therapeutics

Biogen Inc. will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.

Read More »

Pfizer unit Meridian under civil investigation by U.S. Attorney

Pfizer Inc. received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at the company’s Meridian Medical Technologies site.

Read More »

Maze Therapeutics Opens Doors to Study Modifier Gene-Related Diseases

Maze Therapeutics, based in San Francisco, launched with an initial investment of $191 million.

Read More »

Celgene slumps as Bristol-Myers shareholder resists merger

Shares of Celgene Corp. dived 8 percent after a major shareholder in Bristol-Myers Squibb Co. came out against a $74 billion merger that would be the pharmaceutical world’s largest-ever takeover.

Read More »

Mylan shares sink due to bleak profit outlook for 2019

Mylan NV shares slid 10 percent after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if the company’s finances would worsen further.

Read More »

Sarepta to buy Myonexus in gene therapy push

Sarepta Therapeutics will buy privately held gene therapy company Myonexus Therapeutics for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.

Read More »

Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals

Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into.

Read More »

U.S. House Democrats introduce sweeping ‘Medicare for All’ bill

Democrats in the U.S. House of Representatives unveiled an ambitious proposal to move all Americans into the government’s Medicare health insurance program.

Read More »

Immunomedics’ CEO and President Steps Down

Morris Plains, N.J.-based Immunomedics announced that the company’s president, chief executive officer and board member, Michael Pehl, was stepping down for personal reasons.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom